Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)
Makaleler > Tam Makale · 2026
Yazarlar: Cihan Erol, Esra Zeynelgil, Mutlu Hizal, Aysegul Dumludag, Mert Erciyestepe, Ender Kalaci, Sedat Biter, Teoman Sakalar, Merve Keskinkılıc, Seda Kahraman, Selver Isik, Pinar Gursoy, Yasin Kutlu, Yakup Ergun, Ilknur Deliktas, Oguzhan Yildiz, Murat Araz, Sinem Akbas, Pervin Can Sanci, Kazim Uygun, Ziya Kalkan, Dogan Bayram, Dogan Uncu, Sila Oksuz, Nedim Turan, Ozturk Ates, Ahmet Bilici, Saadettin Kilickap, Ilhan Oztop, Serdar Karakaya, Semra Paydas, Ahmet Demirkazik, Nuri Karadurmus, Mehmet Ali Nahit Sendur
Clinical and Translational Oncology, Uluslararası, Wos, 2026